BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pomalidomide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Pomalidomide\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04973605-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Pomalidomide: Phase 1/2 readout est. (NCT04973605)
DESCRIPTION:Pomalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: A Phase 1b
 /2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinat
 ions With Dexamethasone Plus Carfilzomib\, Dexamethasone Plus Daratumumab\
 , and Dexamethasone Plus Pomalidomide in Multiple Myeloma\nEstimated prima
 ry completion: November 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pomalidomide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT04973605
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01562405-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pomalidomide: Phase 1 readout est. (NCT01562405)
DESCRIPTION:Pomalidomide\, phase 1\, Multiple Myeloma.\nStudy: Sotatercept 
 (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/
 Refractory Multiple Myeloma\nEstimated primary completion: December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT01562405
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06855823-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pomalidomide: Phase 1/2 readout est. (NCT06855823)
DESCRIPTION:Pomalidomide\, phase 1/2.\nStudy: A Phase I/II Study of Golidoc
 itinib Combined with Pomalidomide in R/R PTCL\nEstimated primary completio
 n: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pom
 alidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06855823
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06342466-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT06342466)
DESCRIPTION:Pomalidomide\, phase 2.\nStudy: Bortezomib\, Pomalidomide\, Dex
 amethasone for Systemic AL Amyloidosis\nEstimated primary completion: Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pomalidomi
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6342466
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02718833-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT02718833)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: A Study of E
 lotuzumab With Pomalidomide\, Bortezomib\, and Dexamethasone in Relapsed M
 ultiple Myeloma\nEstimated primary completion: December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pomalidomide#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT02718833
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04902443-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Pomalidomide: Phase 1 readout est. (NCT04902443)
DESCRIPTION:Pomalidomide\, phase 1.\nStudy: Pomalidomide and Nivolumab in P
 eople With Virus-Associated Malignancies With or Without HIV\nEstimated pr
 imary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pomalidomide#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04902443
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04883242-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT04883242)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab\,
  Carfilzomib\, Pomalidomide\, and Dexamethasone for the Treatment of Relap
 sed or Refractory Multiple Myeloma\nEstimated primary completion: 31 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pomalidomid
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 883242
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06924424-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pomalidomide: Phase na readout est. (NCT06924424)
DESCRIPTION:Pomalidomide\, phase na\, Multiple Myeloma.\nStudy: Aponermin\,
  Pomalidomide\, Dexamethasone for Patients With Relapsed/ Refractory Multi
 ple Myeloma\nEstimated primary completion: 31 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06924424
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04270175-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT04270175)
DESCRIPTION:Pomalidomide\, phase 2.\nStudy: Daratumumab\, Pomalidomide\, an
 d Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patie
 nts Previously Exposed to Daratumumab\nEstimated primary completion: Janua
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pomalidomide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT042
 70175
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04577755-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270204
DTEND;VALUE=DATE:20270205
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT04577755)
DESCRIPTION:Pomalidomide\, phase 2.\nStudy: Pomalidomide Treatment in Patie
 nts With Kaposi Sarcoma\nEstimated primary completion: 4 February 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04577755
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04508790-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT04508790)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Leflunomide\
 , Pomalidomide\, and Dexamethasone for the Treatment of Relapsed or Refrac
 tory Multiple Myeloma\nEstimated primary completion: 14 February 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04508790
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06660498-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pomalidomide: Phase 1/2 readout est. (NCT06660498)
DESCRIPTION:Pomalidomide\, phase 1/2.\nStudy: Pomalidomide as an Immune-enh
 ancing Agent for the Control of HIV\nEstimated primary completion: 31 Marc
 h 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0666
 0498
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04068597-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pomalidomide: Phase 1/2 readout est. (NCT04068597)
DESCRIPTION:Pomalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: Study to E
 valuate CCS1477 (Inobrodib) in Haematological Malignancies\nEstimated prim
 ary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/pomalidomide#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04068597
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06508983-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT06508983)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Clinical S
 tudy Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus P
 omalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma P
 atients\nEstimated primary completion: 31 March 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06508983
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02343042-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pomalidomide: Phase 1/2 readout est. (NCT02343042)
DESCRIPTION:Pomalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: Selinexor 
 and Backbone Treatments of Multiple Myeloma Patients\nEstimated primary co
 mpletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pomalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT02343042
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04835129-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT04835129)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab\,
  Pomalidomide\, Elotuzumab and Dexamethasone in Relapsed and/or Refractory
  Multiple Myeloma\nEstimated primary completion: 1 April 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04835129
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04108195-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270407
DTEND;VALUE=DATE:20270408
SUMMARY:Pomalidomide: Phase 1 readout est. (NCT04108195)
DESCRIPTION:Pomalidomide\, phase 1\, Multiple Myeloma.\nStudy: A Study of S
 ubcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Red
 irection Antibodies for the Treatment of Participants With Multiple Myelom
 a\nEstimated primary completion: 7 April 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT04108195
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04176718-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT04176718)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Daratumumab\
 , Carfilzomib\, Pomalidomide\, Dexamethasone In MM\nEstimated primary comp
 letion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pom
 alidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04176718
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07072208-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Pomalidomide: Phase na readout est. (NCT07072208)
DESCRIPTION:Pomalidomide\, phase na.\nStudy: Pomalidomide\, Rituximab and O
 relabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly D
 iagnosed Elderly Patients With DLBCL\nEstimated primary completion: 1 May 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070722
 08
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03715478-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Pomalidomide: Phase 1/2 readout est. (NCT03715478)
DESCRIPTION:Pomalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: Multi-Cent
 er Study of GSK2857916 in Combination With Pomalidomide and Dex\nEstimated
  primary completion: 1 June 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pomalidomide#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT03715478
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04124497-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT04124497)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: A Trial for 
 Relapsed and Relapsed/Refractory Multiple Myeloma Patients\nEstimated prim
 ary completion: 1 July 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/pomalidomide#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04124497
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05455320-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT05455320)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study Comp
 aring Talquetamab in Combination With Daratumumab or in Combination With D
 aratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalid
 omide and Dexamethasone in Participants With Multiple Myeloma That Returns
  After Treatment or is Resistant to Treatment\nEstimated primary completio
 n: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/poma
 lidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05455320
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07532525-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pomalidomide: Phase 1 readout est. (NCT07532525)
DESCRIPTION:Pomalidomide\, phase 1.\nStudy: Pomalidomide After CAR T-cell T
 herapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia o
 r Lymphoma\nEstimated primary completion: August 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07532525
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04790474-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT04790474)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Ixazomib-pom
 alidomide-dexamethasone as Second or Third-line Combination Treatment for 
 Patients With Relapsed and Refractory Multiple Myeloma Previously Treated 
 With Daratumumab\, Lenalidomide and Bortezomib\nEstimated primary completi
 on: 1 September 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pomalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04790474
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05556798-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Pomalidomide: Phase 1 readout est. (NCT05556798)
DESCRIPTION:Pomalidomide\, phase 1\, Multiple Myeloma.\nStudy: A Study of B
 elantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in P
 eople With Multiple Myeloma That Has Not Responded to Treatment or Has Com
 e Back After Treatment\nEstimated primary completion: October 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05556798
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04850599-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT04850599)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab\,
  Carfilzomib\, and Pomalidomide for the Treatment of Relapsed or Refractor
 y Multiple Myeloma\nEstimated primary completion: 15 October 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT04850599
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05208307-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20271021
DTEND;VALUE=DATE:20271022
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT05208307)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Belantamab M
 afodotin\, Pomalidomide and Dexamethasone for the Treatment of High-Risk M
 yeloma\nEstimated primary completion: 21 October 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05208307
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018050-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT07018050)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Phase II Stu
 dy of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma\nE
 stimated primary completion: November 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07018050
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742138-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT06742138)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: To Evaluate 
 the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myelom
 a\nEstimated primary completion: December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06742138
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158841-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT06158841)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: Study Assess
 ing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Ava
 ilable Therapies in Adult Participants With Relapsed or Refractory Multipl
 e Myeloma\nEstimated primary completion: December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06158841
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441954-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20271205
DTEND;VALUE=DATE:20271206
SUMMARY:Pomalidomide: Phase 1/2 readout est. (NCT07441954)
DESCRIPTION:Pomalidomide\, phase 1/2.\nStudy: Pomalidomide Combined With Ob
 inutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent 
 Lymphoma\nEstimated primary completion: 5 December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07441954
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06615479-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT06615479)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study to C
 ompare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in A
 dult Participants With Relapsed or Refractory and Lenalidomide-exposed Mul
 tiple Myeloma (QUINTESSENTIAL-2)\nEstimated primary completion: 30 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0661
 5479
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05651932-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pomalidomide: Phase 1 readout est. (NCT05651932)
DESCRIPTION:Pomalidomide\, phase 1\, Multiple Myeloma.\nStudy: A Study of a
 n MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myelom
 a\nEstimated primary completion: 31 December 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05651932
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02659930-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Pomalidomide: Phase 1 readout est. (NCT02659930)
DESCRIPTION:Pomalidomide\, phase 1.\nStudy: Pomalidomide in Combination Wit
 h Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarco
 ma\nEstimated primary completion: 1 January 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT02659930
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06106945-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280124
DTEND;VALUE=DATE:20280125
SUMMARY:Pomalidomide: Phase 1/2 readout est. (NCT06106945)
DESCRIPTION:Pomalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: AZD0305 as
  Monotherapy or in Combination With Anticancer Agents in Participants With
  Multiple Myeloma\nEstimated primary completion: 24 January 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06106945
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04661137-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT04661137)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: A Study of S
 elinexor\, in Combination With Carfilzomib\, Daratumumab or Pomalidomide i
 n Patients With Multiple Myeloma\nEstimated primary completion: February 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0466113
 7
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06879379-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pomalidomide: Phase 2/3 readout est. (NCT06879379)
DESCRIPTION:Pomalidomide\, phase 2/3\, Multiple Myeloma.\nStudy: KPD Consol
 idation After ASCT in NDMM Patients\nEstimated primary completion: March 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0687937
 9
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05137054-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280325
DTEND;VALUE=DATE:20280326
SUMMARY:Pomalidomide: Phase 1 readout est. (NCT05137054)
DESCRIPTION:Pomalidomide\, phase 1\, Multiple Myeloma.\nStudy: A Study to E
 xamine the Effects of Novel Therapy Linvoseltamab in Combination With Othe
 r Cancer Treatments for Adult Participants With Multiple Myeloma That is R
 esistant to Current Standard of Care Treatments\nEstimated primary complet
 ion: 25 March 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 omalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05137054
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07523737-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT07523737)
DESCRIPTION:Pomalidomide\, phase 2.\nStudy: Pomalidomide\, Anti-PD-1 Antibo
 dy Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Ne
 rvous System Diffuse Large B-Cell Lymphoma\nEstimated primary completion: 
 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pomali
 domide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07523737
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07560449-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT07560449)
DESCRIPTION:Pomalidomide\, phase 2.\nStudy: QLS4131 Combination Therapy in 
 Malignant Plasma Cell Neoplasms\nEstimated primary completion: June 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07560449
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05389423-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Pomalidomide: Phase 1 readout est. (NCT05389423)
DESCRIPTION:Pomalidomide\, phase 1.\nStudy: Pomalidomide and Dose-Adjusted 
 EPOCH +/- Rituximab for HIV-Associated Lymphomas\nEstimated primary comple
 tion: 1 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/po
 malidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05389423
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07760610-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Pomalidomide: Phase 4 readout est. (NCT07760610)
DESCRIPTION:Pomalidomide\, phase 4.\nStudy: Pomalidomide Plus Rituximab Mai
 ntenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Respons
 e\nEstimated primary completion: July 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07760610
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05789303-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT05789303)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Study of Bel
 antamab Mafodotin With Carfilzomib\, Pomalidomide\, and Dexamethasone in R
 elapsed Multiple Myeloma\nEstimated primary completion: 1 July 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05789303
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07257510-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Pomalidomide: Phase na readout est. (NCT07257510)
DESCRIPTION:Pomalidomide\, phase na.\nStudy: Pomalidomide Plus Orelabrutini
 b and Zuberitamab in Untreated Mantle Cell Lymphoma\nEstimated primary com
 pletion: 1 August 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/pomalidomide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07257510
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05714839-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280803
DTEND;VALUE=DATE:20280804
SUMMARY:Pomalidomide: Phase 1/2 readout est. (NCT05714839)
DESCRIPTION:Pomalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to
  Investigate the Safety and Efficacy of Belantamab for the Treatment of Mu
 ltiple Myeloma When Used as Monotherapy and in Combination Treatments\nEst
 imated primary completion: 3 August 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05714839
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05669989-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT05669989)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Internationa
 l Treatment-extension Study in Adult Participants With Multiple Myeloma an
 d Who Have Derived Clinical Benefit From Isatuximab\nEstimated primary com
 pletion: 30 November 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pomalidomide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05669989
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07555938-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT07555938)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: Cevostamab i
 n Combination With Pomalidomide and Dexamethasone Versus Standard of Care 
 in Participants With Previously Treated Multiple Myeloma\nEstimated primar
 y completion: 30 November 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pomalidomide#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07555938
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04910568-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:Pomalidomide: Phase 1 readout est. (NCT04910568)
DESCRIPTION:Pomalidomide\, phase 1\, Multiple Myeloma.\nStudy: A Study Eval
 uating the Safety\, Pharmacokinetics\, and Activity of Cevostamab in Parti
 cipants With Relapsed or Refractory Multiple Myeloma\nEstimated primary co
 mpletion: 21 December 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pomalidomide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04910568
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05922501-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT05922501)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab\,
  Bela Maf\, Pom\, and Dex in Relapsed/Refractory Multiple Myeloma\nEstimat
 ed primary completion: 31 December 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05922501
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07757412-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT07757412)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Teclistamab 
 in Combination With Pomalidomide Administered in Alternative Fashion in Pa
 rticipants With Relapsed or Refractory Multiple Myeloma.\nEstimated primar
 y completion: 1 January 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pomalidomide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07757412
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06768489-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290102
DTEND;VALUE=DATE:20290103
SUMMARY:Pomalidomide: Phase 1 readout est. (NCT06768489)
DESCRIPTION:Pomalidomide\, phase 1\, Multiple Myeloma.\nStudy: A Study of R
 amantamig in Combination With Daratumumab With or Without Lenalidomide or 
 of Single-agent JNJ-102299639 for Multiple Myeloma\, Newly Diagnosed AL Am
 yloidosis\, and High-risk Smoldering Multiple Myeloma or Ramantamig in Com
 bination With Pomalidomide for Multiple Myeloma\nEstimated primary complet
 ion: 2 January 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pomalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06768489
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05438043-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT05438043)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study of D
 aratumumab\nEstimated primary completion: 31 January 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05438043
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07463807-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Pomalidomide: Phase 1/2 readout est. (NCT07463807)
DESCRIPTION:Pomalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: Testing th
 e Investigational Medication Combination of Teclistamab and Pomalidomide C
 ompared to the Usual Treatment (Carfilzomib\, Pomalidomide\, and Dexametha
 sone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After T
 reatment\nEstimated primary completion: 31 March 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07463807
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07825064-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290413
DTEND;VALUE=DATE:20290414
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT07825064)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Cevostamab i
 n Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CA
 R T-Cell Therapy in Participants With Previously Treated Multiple Myeloma\
 nEstimated primary completion: 13 April 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07825064
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222761-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290521
DTEND;VALUE=DATE:20290522
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT07222761)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study to C
 ompare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combinati
 on Therapy With Standard-of-Care Combination Regimens in Adult Participant
 s With Relapsed/Refractory Multiple Myeloma (RRMM)\nEstimated primary comp
 letion: 21 May 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pomalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07222761
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07772024-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT07772024)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: Inobrodib\, 
 Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relaps
 ed or Refractory Multiple Myeloma\nEstimated primary completion: November 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077720
 24
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07096778-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT07096778)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Inobrodib\, 
 Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma\
 nEstimated primary completion: 1 December 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07096778
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07749365-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT07749365)
DESCRIPTION:Pomalidomide\, phase 2.\nStudy: Hypofractionated Radiotherapy P
 lus GM-CSF\, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL\nE
 stimated primary completion: 31 December 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07749365
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720843-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Pomalidomide: Phase 1 readout est. (NCT07720843)
DESCRIPTION:Pomalidomide\, phase 1\, Multiple Myeloma.\nStudy: TAlquetamab 
 and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)
 \nEstimated primary completion: March 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07720843
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227311-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20300830
DTEND;VALUE=DATE:20300831
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT07227311)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: A Study to E
 valuate the Efficacy and Safety of Belantamab Mafodotin in Combination Wit
 h Standard of Care in Participants With Relapsed-Refractory Multiple Myelo
 ma (RRMM)\nEstimated primary completion: 30 August 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07227311
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07831122-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20330131
DTEND;VALUE=DATE:20330201
SUMMARY:Pomalidomide: Phase 1 readout est. (NCT07831122)
DESCRIPTION:Pomalidomide\, phase 1\, Multiple Myeloma.\nStudy: Study of Bel
 antamab Mafodotin\, Cevostamab\, Pomalidomide for RRMM Patients (MAPLE)\nE
 stimated primary completion: January 2033. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07831122
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07728188-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20330228
DTEND;VALUE=DATE:20330301
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT07728188)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study to E
 valuate Adverse Events and Change in Disease Activity With Injected Etenta
 mig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relaps
 ed or Refractory Multiple Myeloma\nEstimated primary completion: February 
 2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077281
 88
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748689-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20330331
DTEND;VALUE=DATE:20330401
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT07748689)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Comparing Lo
 wer Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and De
 xamethasone in Relapsed or Refractory Multiple Myeloma.\nEstimated primary
  completion: March 2033. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pomalidomide#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07748689
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05259839-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20330930
DTEND;VALUE=DATE:20331001
SUMMARY:Pomalidomide: Phase 1 readout est. (NCT05259839)
DESCRIPTION:Pomalidomide\, phase 1\, Multiple Myeloma.\nStudy: A Study to A
 ssess Adverse Events and Change in Disease Activity of Intravenously (IV) 
 Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for 
 the Treatment of Adult Participants With Relapsed/Refractory Multiple Myel
 oma\nEstimated primary completion: September 2033. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05259839
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892522-3123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Pomalidomide: Phase 1/2 readout est. (NCT06892522)
DESCRIPTION:Pomalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to
  Assess Change in Disease Activity and Adverse Events (AE)s in Adult Parti
 cipants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific An
 tibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations\n
 Estimated primary completion: December 2035. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06892522
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
